<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Phys Med Biol</journal-id><journal-id journal-id-type="iso-abbrev">Phys Med Biol</journal-id><journal-id journal-id-type="publisher-id">pmb</journal-id><journal-id journal-id-type="coden">PHMBA7</journal-id><journal-title-group><journal-title>Physics in Medicine and Biology</journal-title></journal-title-group><issn pub-type="ppub">0031-9155</issn><issn pub-type="epub">1361-6560</issn><publisher><publisher-name>IOP Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5953197</article-id><article-id pub-id-type="publisher-id">pmbaa5e6f</article-id><article-id pub-id-type="doi">10.1088/1361-6560/aa5e6f</article-id><article-id pub-id-type="publisher-manuscript">aa5e6f</article-id><article-id pub-id-type="other">PMB-104988.R1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Paper</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="ascii">A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Denis-Bacelar</surname><given-names>Ana M</given-names></name><xref ref-type="aff" rid="pmbaa5e6faf1">1</xref><xref ref-type="author-notes" rid="pmbaa5e6ffn5">5</xref><xref ref-type="aff" rid="pmbaa5e6fem1"/></contrib><contrib contrib-type="author"><name><surname>Chittenden</surname><given-names>Sarah J</given-names></name><xref ref-type="aff" rid="pmbaa5e6faf1">1</xref></contrib><contrib contrib-type="author"><name><surname>Murray</surname><given-names>Iain</given-names></name><xref ref-type="aff" rid="pmbaa5e6faf1">1</xref></contrib><contrib contrib-type="author"><name><surname>Divoli</surname><given-names>Antigoni</given-names></name><xref ref-type="aff" rid="pmbaa5e6faf1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ralph McCready</surname><given-names>V</given-names></name><xref ref-type="aff" rid="pmbaa5e6faf2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dearnaley</surname><given-names>David P</given-names></name><xref ref-type="aff" rid="pmbaa5e6faf3">3</xref></contrib><contrib contrib-type="author"><name><surname>O’Sullivan</surname><given-names>Joe M</given-names></name><xref ref-type="aff" rid="pmbaa5e6faf4">4</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Bernadette</given-names></name><xref ref-type="aff" rid="pmbaa5e6faf3">3</xref></contrib><contrib contrib-type="author"><name><surname>Flux</surname><given-names>Glenn D</given-names></name><xref ref-type="aff" rid="pmbaa5e6faf1">1</xref></contrib><aff id="pmbaa5e6faf1"><label>1</label>Joint Department of Physics, <institution>The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust</institution>, London, <country>United Kingdom</country></aff><aff id="pmbaa5e6faf2"><label>2</label>Department of Nuclear Medicine, <institution>Brighton and Sussex University Hospitals NHS Trust</institution>, Brighton, <country>United Kingdom</country></aff><aff id="pmbaa5e6faf3"><label>3</label>Division of Radiotherapy and Imaging, <institution>The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust</institution>, London, <country>United Kingdom</country></aff><aff id="pmbaa5e6faf4"><label>4</label>Centre for Cancer Research and Cell Biology, <institution>Queen’s University Belfast</institution>, Belfast, <country>United Kingdom</country></aff><aff id="pmbaa5e6fem1" content-type="email"><email>ana.denisbacelar@icr.ac.uk</email></aff><author-comment content-type="short-author-list"><p>A M Denis-Bacelar <italic>et al</italic></p></author-comment></contrib-group><author-notes><corresp id="pmbaa5e6ffn5"><label>5</label>Author to whom any correspondence should be addressed. Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital NHS FT, London, SM2 5NG, United Kingdom.</corresp></author-notes><pub-date pub-type="ppub"><day>7</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>14</day><month>3</month><year>2017</year></pub-date><volume>62</volume><issue>7</issue><fpage>2859</fpage><lpage>2870</lpage><history><date date-type="received"><day>11</day><month>11</month><year>2016</year></date><date date-type="rev-recd"><day>5</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>6</day><month>2</month><year>2017</year></date><date date-type="oa-requested"><day>15</day><month>11</month><year>2016</year></date><date date-type="open-access"><day>14</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 Institute of Physics and Engineering in Medicine</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>
Original content from this work may be used under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">Creative Commons Attribution 3.0 licence</ext-link>. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="https://doi.org/10.1088/1361-6560/aa5e6f"/><abstract><title><text><SENT sid="1" pm="."><plain>Abstract </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. </plain></SENT>
<SENT sid="3" pm="."><plain>This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function of the absorbed doses delivered from molecular radiotherapy treatments. </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>The range of absorbed doses necessary to eradicate all the bone lesions and to reduce the metastatic burden was investigated in a cohort of 22 patients with bone metastases from castration-resistant prostate cancer. </plain></SENT>
<SENT sid="5" pm="."><plain>A metastatic burden reduction curve was generated for each patient, which predicts the reduction in metastatic burden as a function of the patient mean absorbed dose, defined as the mean of all the lesion absorbed doses in any given patient. </plain></SENT>
<SENT sid="6" pm="."><plain>In the patient cohort studied, the median of the patient mean absorbed dose predicted to reduce the metastatic burden by 50% was 89 Gy (interquartile range: 83–105 Gy), whilst a median of 183 Gy (interquartile range: 107–247 Gy) was found necessary to eradicate all metastases in a given patient. </plain></SENT>
<SENT sid="7" pm="."><plain>The absorbed dose required to eradicate all the lesions was strongly correlated with the variability of the absorbed doses delivered to multiple lesions in a given patient (r  =  0.98, P  &lt;  0.0001). </plain></SENT>
<SENT sid="8" pm="."><plain>The metastatic burden reduction curves showed a potential large reduction in metastatic burden for a small increase in absorbed dose in 91% of patients. </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="9" pm="."><plain>The results indicate the range of absorbed doses required to potentially obtain a significant survival benefit. </plain></SENT>
<SENT sid="10" pm="."><plain>The metastatic burden reduction method provides a simple tool that could be used in routine clinical practice for patient selection and to indicate the required administered activity to achieve a predicted patient mean absorbed dose and reduction in metastatic tumour burden. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author"><kwd>radiobiology</kwd><kwd>dosimetry</kwd><kwd>radiopharmaceuticals</kwd><kwd>bone metastases</kwd><kwd>prostate cancer</kwd><kwd>molecular radiotherapy</kwd></kwd-group></SecTag><funding-group><award-group><funding-source>National Cancer Institute<named-content content-type="funder-id">https://doi.org/10.13039/100000054</named-content></funding-source><award-id>CA86784-02</award-id></award-group><award-group><funding-source>Cancer Research UK<named-content content-type="funder-id">https://doi.org/10.13039/501100000289</named-content></funding-source><award-id>C1060/A10334</award-id><award-id>C1060/A16464</award-id></award-group></funding-group><counts><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>ccc</meta-name><meta-value>1361-6560/17/072859+12$33.00</meta-value></custom-meta><custom-meta><meta-name>printed</meta-name><meta-value>Printed in the UK</meta-value></custom-meta><custom-meta><meta-name>crossmark</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="pmbaa5e6fs1"><title><text><SENT sid="11" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="12" pm="."><plain>Bone metastases are a common indicator of distant relapse from various cancers, in particular those arising in the prostate, lung and breast (Mundy 2002). </plain></SENT>
<SENT sid="13" pm="."><plain>They can lead to complications such as severe pain, pathological fractures and spinal cord compression; which significantly decrease patient quality of life and shorten survival (Coleman 2001). </plain></SENT>
<SENT sid="14" pm="."><plain>Current treatments for patients with bone metastases are primarily palliative, including the use of analgesics, external beam radiotherapy, bisphosphonates, chemotherapy or molecular radiotherapy with bone-seeking radiopharmaceuticals (Coleman 2001). </plain></SENT>
</text></p><p><text><SENT sid="15" pm="."><plain>Radiation therapy is an effective treatment modality for bone pain palliation and evidence has shown equal pain relief for single and multi-fraction treatments, providing pain relief in up to 80% of patients (Chow et al 2012). </plain></SENT>
<SENT sid="16" pm="."><plain>The biological effects of radiation in a curative cancer treatment are not as relevant to a palliative setting, as low absorbed doses are used for bone pain palliation in contrast to the higher levels of radiation required for tumour eradication. </plain></SENT>
<SENT sid="17" pm="."><plain>However, recent treatment advances in stereotactic body radiation therapy (SBRT) have enabled the safe delivery of ablative radiation doses with minimal normal tissue toxicity to patients with low number of metastases and oligometastatic disease (Tree et al 2013, Saluja et al 2016). </plain></SENT>
<SENT sid="18" pm="."><plain>Molecular radiotherapy with bone-seeking radiopharmaceuticals can also potentially deliver high absorbed doses to the bone lesions cells whilst minimising bone marrow toxicity (Goyal and Antonarakis 2012). </plain></SENT>
<SENT sid="19" pm="."><plain>A survival benefit has been observed for 89Sr-dichloride following 6 weekly cycles of doxorubicin as compared to chemotherapy alone in patients with metastatic castration-resistant prostate cancer (mCRPC) (Tu et al 2001). </plain></SENT>
<SENT sid="20" pm="."><plain>More recently, 223Ra-dichloride was shown to improve survival against placebo (Parker et al 2013), introducing a shift in patient management from pain palliation to prolonged survival (Liepe and Shinto 2016). </plain></SENT>
<SENT sid="21" pm="."><plain>The prospect of further significant improvements in survival is underlined by the limited haematological toxicity resulting from current treatments (Bruland et al 2006, Parker et al 2013) and the practicality of high activity administrations in combination with stem cell transplantation (O’Sullivan et al 2002, O’Sullivan 2006). </plain></SENT>
<SENT sid="22" pm="."><plain>This indicates the potential for more aggressive administrations if a personalised treatment planning approach is used. </plain></SENT>
<SENT sid="23" pm="."><plain>Such treatments require quantification of image data to facilitate patient-specific dosimetry and the development of models to explain the clinical significance of the calculated absorbed doses. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>Available radiobiological models of metastatic control provide the probability of eradicating all the metastases in a given patient (Bernhardt et al 2003, 2004). </plain></SENT>
<SENT sid="25" pm="."><plain>Numerous studies have shown that the skeletal tumour burden (Soloway et al 1988, Dennis et al 2012, Denis-Bacelar et al 2017) is closely related to overall survival. </plain></SENT>
<SENT sid="26" pm="."><plain>Therefore, a more clinically realistic measure of metastatic control would be to consider the reduction in metastatic burden and prevention of spread of the disease rather than complete cure. </plain></SENT>
<SENT sid="27" pm="."><plain>The aim of this study was to propose a new method to predict the decrease of metastatic burden for any given patient-specific distribution of lesion absorbed doses following radiotherapy. </plain></SENT>
<SENT sid="28" pm="."><plain>The application of this methodology in clinical practice was assessed using available clinical data from patients with mCRPC, which reveals a new framework within which the potential for prolonged survival and metastatic tumour burden reduction could be explored. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="pmbaa5e6fs2"><title><text><SENT sid="29" pm="."><plain>Material and methods </plain></SENT>
</text></title><p><text><SENT sid="30" pm="."><plain>Ionising radiation induces DNA damage mainly via single and double-strand breaks, which can lead to cell death. </plain></SENT>
<SENT sid="31" pm="."><plain>The linear quadratic (LQ) model is commonly used to describe cell kill from tissue irradiation (Dale 1985), where the cell survival fraction is given as: 1\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}\begin{eqnarray*}\text{SF}(D)={{\text{e}}^{-\left(\alpha D+\beta G{{D}^{2}}\right)}},\end{eqnarray*}\end{document}SF(D)=e−(αD+βGD2), where α (Gy−1) and β (Gy−2) are tissue dependent constants used to describe the probability of cell death by double-strand breaks and by two consecutive single-strand breaks to occur respectively. </plain></SENT>
<SENT sid="32" pm="."><plain>Repopulation effects were not considered. </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>Considerably lower absorbed dose rates are delivered in molecular radiotherapy as compared to external beam radiotherapy; therefore the contribution from the quadratic component is smaller, as many of the single-strand breaks are repaired during irradiation. </plain></SENT>
<SENT sid="34" pm="."><plain>To account for the repair of sub-lethal damage from protracted irradiation during a time T, the quadratic component of the LQ model is modified by the Lea–Catcheside factor (G) (Millar 1991, Gerweck et al 2006): 2\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}\begin{eqnarray*}G(T)=\frac{2}{{{D}^{2}}}{\int}_{0}^{T}\text{d}t\frac{\text{d}D(t)}{\text{d}t}{\int}_{0}^{t}\text{d}{{t}^{\prime}}\frac{\text{d}D\left({{t}^{\prime}}\right)}{\text{d}{{t}^{\prime}}}{{\text{e}}^{-\mu \left(t-{{t}^{\prime}}\right)}}.\end{eqnarray*}\end{document}G(T)=2D2∫0TdtdD(t)dt∫0tdt′dD(t′)dt′e−μ(t−t′). </plain></SENT>
</text></p><p><text><SENT sid="35" pm="."><plain>For molecular radiotherapy, with a mono-exponentially decreasing absorbed dose rate which is allowed to decay (T  →  ∞): 3\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}\begin{eqnarray*}G\left(\infty \right)=\frac{\lambda}{\lambda +\mu},\end{eqnarray*}\end{document}G(∞)=λλ+μ, where λ is the effective decay constant which accounts for the physical and biological half-lives of a given radiopharmaceutical, and μ is the repair rate constant. </plain></SENT>
<SENT sid="36" pm="."><plain>Typical sub-lethal damage repair half-times range between 16 min and 3 h (Dale and Carabe-Fernandez 2005). </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>The biological effective dose (BED) accounts for the effects of the absorbed dose rate and the radiosensitivity and repair capacity of the considered tissue (Fowler 1989): 4\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}\begin{eqnarray*}\text{BED}=-\frac{\ln \left(\text{SF}\right)}{\alpha}=D\left(1+\lambda \frac{D}{\left(\lambda +\mu \right){}^{\alpha}/{}_{\beta}}\right),\end{eqnarray*}\end{document}BED=−ln(SF)α=D(1+λD(λ+μ)αβ), where the α/β ratio quantifies the radiosensitivity of a given tissue to changes in fractionation and Dλ is the initial absorbed dose rate of the radiopharmaceutical. </plain></SENT>
<SENT sid="38" pm="."><plain>Typical ratios for tumours and early-reacting tissues including the bone marrow are 10 Gy, whilst late-responding tissues show ratios of 2–5 Gy (Dale 2004). </plain></SENT>
<SENT sid="39" pm="."><plain>Prostate cancer is an exception, where most studies indicate low ratios of about 1–5 Gy (Brenner and Hall 1999, Fowler et al 2001, Wang et al 2003, Oliveira et al 2012, Dearnaley et al 2016). </plain></SENT>
<SENT sid="40" pm="."><plain>An average effective half-life of 62 h was used (Graham et al 1999). </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>From the LQ model and considering Poisson statistics, the tumour control probability (TCP) expresses the probability of killing all clonogenic cells (N0) in a given bone lesion: 5\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}\begin{eqnarray*}\text{TCP}=\exp \left(-{{N}_{0}}\times \text{SF}\right)=\exp \left(-{{\rho}_{\text{c}}}V\times \exp \left(-\alpha \text{BED}\right)\right),\end{eqnarray*}\end{document}TCP=exp(−N0×SF)=exp(−ρcV×exp(−αBED)), where ρc is the clonogenic cell density and V is the tumour volume. </plain></SENT>
</text></p><p><text><SENT sid="42" pm="."><plain>The absorbed doses required to obtain a TCP of 0.95 depend on the radiobiological parameters used, however these are not known for radionuclides and bone lesions from prostate cancer. </plain></SENT>
<SENT sid="43" pm="."><plain>The results of this study are based on parameters corresponding to prostate cancer cells, with a clonogenic cell density of 3 · 106 cm−3, α/β of 3.1 Gy, α of 0.15 Gy−1 and repair constant μ of 0.46 h−1 (Wang et al 2003). </plain></SENT>
</text></p><sec id="pmbaa5e6fs2-1"><title><text><SENT sid="44" pm="."><plain>The metastatic control probability model </plain></SENT>
</text></title><p><text><SENT sid="45" pm="."><plain>The metastatic control probability (MCP) model (Bernhardt et al 2003, 2004), has been previously used in molecular radiotherapy (Elgqvist et al 2010, Walrand et al 2012). </plain></SENT>
<SENT sid="46" pm="."><plain>In the context of skeletal metastases, it provides the probability of eradicating all the bone lesions in a given patient and it is defined as the product of the N individual lesion TCPs: 6\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}\begin{eqnarray*}\text{MCP}=\underset{i=1}{\overset{N}{{ \Pi }}}\,_{\,}^{{}}\text{TCP}.\end{eqnarray*}\end{document}MCP=Πi=1N TCP. </plain></SENT>
</text></p></sec><sec id="pmbaa5e6fs2-2"><title><text><SENT sid="47" pm="."><plain>The metastatic burden reduction model </plain></SENT>
</text></title><p><text><SENT sid="48" pm="."><plain>A new framework for treatment planning is proposed, where the decrease in metastatic tumour burden is predicted as a function of the absorbed doses delivered to multiple bone lesions. </plain></SENT>
<SENT sid="49" pm="."><plain>If the patient mean absorbed dose (PMAD) is defined as the mean of N lesion absorbed doses in any given patient (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}$\text{PMAD}={\sum}_{i=0}^{N}{{D}_{i}}/N$ \end{document}PMAD=∑i=0NDi/N), the metastatic burden reduction (MBR) following treatment is calculated as: 7\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}\begin{eqnarray*}\text{MBR}\left(\text{PMAD}\right)=1-\frac{{\sum}_{i=0}^{N}\,{{v}_{i}}\times {{k}_{i}}\left({{D}_{i}}\right)}{V},\end{eqnarray*}\end{document}MBR(PMAD)=1−∑i=0N vi×ki(Di)V, where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}$V={\sum}_{i=0}^{N}{{v}_{i}}$ \end{document}V=∑i=0Nvi is the metastatic burden at baseline calculated as the sum of the volumes for N lesions of volume vi, and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}${{k}_{i}}\left({{D}_{i}}\right)=\left\{\begin{array}{*{35}{l}} 1, &amp;amp; TCP\left({{D}_{i}}\right)&amp;lt;0.95 \\ 0, &amp;amp; TCP\left({{D}_{i}}\right)\geqslant 0.95 \end{array}\right. $ \end{document}ki(Di)={1,TCP(Di)&lt;0.950,TCP(Di)⩾0.95 is a binary parameter that describes the eradicated (k  =  0) or non-eradicated (k  =  1) status of the ith lesion for a given lesion absorbed dose Di. </plain></SENT>
<SENT sid="50" pm="."><plain>The MBR ranges from 0 (no metastases have been eradicated) to 1 (all metastases have been eradicated). </plain></SENT>
</text></p></sec><sec id="pmbaa5e6fs2-3"><title><text><SENT sid="51" pm="."><plain>Application to clinical data </plain></SENT>
</text></title><p><text><SENT sid="52" pm="."><plain>Clinical data were obtained from 22 patients with CRPC metastatic to bone treated with a fixed administered activity of 5 GBq of 186Re-HEDP and with peripheral blood stem cell transplant support during a phase II clinical trial (O’Sullivan 2006). </plain></SENT>
<SENT sid="53" pm="."><plain>All patients provided written informed consent to take part in the trials, which were approved by the Royal Marsden NHS Trust and The Institute of Cancer Research Ethics committee. </plain></SENT>
<SENT sid="54" pm="."><plain>Bone lesion dosimetry and skeletal metastatic tumour burden calculations were performed from quantitative sequential SPECT imaging as part of a previous study (Denis-Bacelar et al 2017). </plain></SENT>
<SENT sid="55" pm="."><plain>The delivered patient mean absorbed dose (PMADdelivered) was defined as the mean of the absorbed doses delivered to all lesions in any given patient. </plain></SENT>
<SENT sid="56" pm="."><plain>The relative distribution of lesion absorbed doses and the lesion volumes were used as the basis for the radiobiology calculations. </plain></SENT>
</text></p><p><text><SENT sid="57" pm="."><plain>Calculations of the TCP were performed under the assumption of uniform absorbed dose distributions within the bone lesion and uniform radiosensitivity and clonogenic density across lesions and patients. </plain></SENT>
<SENT sid="58" pm="."><plain>The patient mean absorbed dose necessary to eradicate all the bone lesions within a patient (PMADMCP=0.95) was obtained by iteratively scaling the relative distribution of absorbed doses delivered to the lesions in a given patient by a target dose scaling factor until MCP  =  0.95. </plain></SENT>
</text></p><p><text><SENT sid="59" pm="."><plain>To assess the impact of the degree of absorbed dose variability between lesions upon the PMADMCP=0.95, different measures of variability were considered; including the range, variance, standard deviation, coefficient of variation and the range scaled by the minimum value. </plain></SENT>
</text></p><p><text><SENT sid="60" pm="."><plain>The patient mean absorbed dose at which the metastatic tumour reduction is 100% approaches PMADMCP=0.95. </plain></SENT>
<SENT sid="61" pm="."><plain>Metastatic tumour reduction curves were obtained for a range of patient mean absorbed doses derived from scaling the relative distribution of absorbed doses delivered to the lesions for all patients. </plain></SENT>
<SENT sid="62" pm="."><plain>The patient mean absorbed dose required to decrease the metastatic tumour burden by 50% (PMADMBR=0.5) was calculated for each patient. </plain></SENT>
</text></p><p><text><SENT sid="63" pm="."><plain>To assess the impact of the cut-off probability on the metastatic control and metastatic burden reduction, the calculations were also performed for values of 0.9 and 0.99. </plain></SENT>
<SENT sid="64" pm="."><plain>The effect of an α parameter of 0.25 Gy−1 to represent metastatic lesions less radio-resistant than prostate cancer cells was also characterised. </plain></SENT>
</text></p><sec id="pmbaa5e6fs2-3-1"><title><text><SENT sid="65" pm="."><plain>Comparison between predicted and delivered absorbed doses </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>The predicted PMADMCP=0.95 and PMADMBR=0.5 values for the 22 patients were compared with the PMADdelivered from 5 GBq of 186Re-HEDP. </plain></SENT>
<SENT sid="67" pm="."><plain>Follow-up imaging was not available to determine the actual metastatic burden reduction following treatment. </plain></SENT>
</text></p></sec></sec><sec id="pmbaa5e6fs2-4"><title><text><SENT sid="68" pm="."><plain>Statistical considerations </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>Median and interquartile range (IQR) were used to describe continuous variables. </plain></SENT>
<SENT sid="70" pm="."><plain>Pearson’s correlation coefficients were used to quantify the degree to which two variables are related and regression analysis was used to identify relationships between variables. </plain></SENT>
<SENT sid="71" pm="."><plain>Two-sided P-values below 0.05 were considered significant. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="pmbaa5e6fs3"><title><text><SENT sid="72" pm="."><plain>Results </plain></SENT>
</text></title><sec id="pmbaa5e6fs3-1"><title><text><SENT sid="73" pm="."><plain>The metastatic control probability model </plain></SENT>
</text></title><p><text><SENT sid="74" pm="."><plain>A median PMADMCP=0.95 of 183 Gy (IQR: 107–247 Gy) was obtained across the 22 patients. </plain></SENT>
<SENT sid="75" pm="."><plain>For cut-offs of 0.9 and 0.99 the PMAD median values of 178 Gy (IQR: 104–241 Gy) and 193 Gy (IQR: 113–260 Gy) were obtained respectively. </plain></SENT>
<SENT sid="76" pm="."><plain>An α parameter of 0.25 Gy−1 reduced the PMADMCP=0.95 by 32% on average, with a median of 125 Gy (IQR: 73–169 Gy). </plain></SENT>
<SENT sid="77" pm="."><plain>Figure 1(a) shows a strong negative correlation and power relationship between the target dose scaling factor and the minimum lesion absorbed dose (r  =  −0.89, P  &lt;  0.0001). </plain></SENT>
<SENT sid="78" pm="."><plain>This indicates the strong influence of the minimum absorbed dose in the probability of metastatic control. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pmbaa5e6ff01" orientation="portrait" position="float"><label>Figure 1.</label><caption><p><text><SENT sid="79" pm="."><plain>Relationships between the target dose scaling factor and the minimum lesion absorbed dose in a given patient (a), and between the patient mean absorbed dose required to eradicate all the lesions (PMADMCP=0.95) and the variability of the distribution of absorbed doses delivered to the lesions in a given patient represented by the relative difference between minimum and maximum lesion absorbed doses (b). </plain></SENT>
<SENT sid="80" pm="."><plain>The 95% confidence bands are shown. </plain></SENT>
</text></p></caption><alternatives><graphic id="pmbaa5e6ff01_eps" content-type="print" specific-use="print-only" xlink:href="pmbaa5e6ff01_pr"/><graphic id="pmbaa5e6ff01_online" content-type="online" specific-use="web-only" xlink:href="pmbaa5e6ff01_online"/><graphic id="pmbaa5e6ff01_hr" content-type="high" xlink:href="pmbaa5e6ff01_hr"/></alternatives></fig></SecTag><p><text><SENT sid="81" pm="."><plain>From all the measures of absorbed dose variability in a given patient, the best correlation with the PMADMCP=0.95 was obtained with the range scaled by the minimum absorbed dose (r  =  0.98, P  &lt;  0.0001), shown in figure 1(b). </plain></SENT>
<SENT sid="82" pm="."><plain>When the ratio between the maximum and minimum lesion absorbed dose increases by an order of magnitude, the patient mean absorbed dose required to eradicate all the lesions increases more than 300% (from 49 Gy to 200 Gy for a ratio of 1–10 respectively), highlighting the negative effects of absorbed dose variability between lesions. </plain></SENT>
</text></p></sec><sec id="pmbaa5e6fs3-2"><title><text><SENT sid="83" pm="."><plain>The metastatic burden reduction model </plain></SENT>
</text></title><p><text><SENT sid="84" pm="."><plain>The metastatic burden reduction curves for the 22 patients are shown in figure 2. </plain></SENT>
<SENT sid="85" pm="."><plain>The PMADMBR=0.5 was 89 Gy (IQR: 83–105 Gy) across all patients. </plain></SENT>
<SENT sid="86" pm="."><plain>For cut-offs of 0.9 and 0.99 in the TCP calculation, PMAD median values of 88 Gy (IQR: 81–106 Gy) and 93 Gy (IQR: 89–111 Gy) were obtained respectively. </plain></SENT>
<SENT sid="87" pm="."><plain>An α parameter of 0.25 Gy−1 reduced the PMADMCP=0.95 by 31% on average, with a median of 61 Gy (IQR: 57–73 Gy).Steep gradients were observed for 20 of the 22 patients, which show the potential for a large increase in metastatic burden reduction for a small increase in the patient mean absorbed dose delivered. </plain></SENT>
<SENT sid="88" pm="."><plain>Examination of the individual disease distribution for patients 3 and 4, showed that both had the highest variability in lesion absorbed doses within the patient cohort. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pmbaa5e6ff02" orientation="portrait" position="float"><label>Figure 2.</label><caption><p><text><SENT sid="89" pm="."><plain>Predicted metastatic burden reduction curves obtained for a cohort of 22 patients as a function of the patient mean absorbed dose. </plain></SENT>
<SENT sid="90" pm="."><plain>Patients 3 (*) and 4 (**) are indicated. </plain></SENT>
</text></p></caption><alternatives><graphic id="pmbaa5e6ff02_eps" content-type="print" specific-use="print-only" xlink:href="pmbaa5e6ff02_pr"/><graphic id="pmbaa5e6ff02_online" content-type="online" specific-use="web-only" xlink:href="pmbaa5e6ff02_online"/><graphic id="pmbaa5e6ff02_hr" content-type="high" xlink:href="pmbaa5e6ff02_hr"/></alternatives></fig></SecTag></sec><sec id="pmbaa5e6fs3-3"><title><text><SENT sid="91" pm="."><plain>Clinical dosimetry </plain></SENT>
</text></title><p><text><SENT sid="92" pm="."><plain>Our previous study found a total of 379 lesions identified in 22 patients with a median of 11 lesions (IQR: 3–25) and 227 ml of metastatic tumour burden (IQR: 81–300 ml) per patient. </plain></SENT>
<SENT sid="93" pm="."><plain>The median PMADdelivered across all patients was 19 Gy (IQR: 14–23 Gy) or 3.72 Gy GBq−1 (IQR: 2.80–4.69 Gy GBq−1). </plain></SENT>
<SENT sid="94" pm="."><plain>Further details can be found in Denis-Bacelar et al (2017). </plain></SENT>
</text></p></sec><sec id="pmbaa5e6fs3-4"><title><text><SENT sid="95" pm="."><plain>Comparison between predicted and delivered absorbed doses </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>Table 1 and figure 3 summarize the results obtained for the patient cohort studied. </plain></SENT>
<SENT sid="97" pm="."><plain>The median PMADMCP=0.95 was 183 Gy (IQR: 107–247 Gy), the PMADMBR=0.5 was 89 Gy (IQR: 83–105 Gy) and the median PMADdelivered dose was 19 Gy (IQR: 14–23 Gy). </plain></SENT>
</text></p><SecTag type="TABLE"></SecTag><SecTag type="FIG"><fig id="pmbaa5e6ff03" orientation="portrait" position="float"><label>Figure 3.</label><caption><p><text><SENT sid="241" pm="."><plain>Range of predicted PMADMCP=0.95 and PMADMBR=0.5, and delivered PMADdelivered for the 22 patients. </plain></SENT>
<SENT sid="242" pm="."><plain>The median and inter-quartile range is shown. </plain></SENT>
</text></p></caption><alternatives><graphic id="pmbaa5e6ff03_eps" content-type="print" specific-use="print-only" xlink:href="pmbaa5e6ff03_pr"/><graphic id="pmbaa5e6ff03_online" content-type="online" specific-use="web-only" xlink:href="pmbaa5e6ff03_online"/><graphic id="pmbaa5e6ff03_hr" content-type="high" xlink:href="pmbaa5e6ff03_hr"/></alternatives></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="pmbaa5e6fs4"><title><text><SENT sid="243" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="244" pm="."><plain>Standard radiobiological models of metastatic control were used to assess the patient-specific absorbed doses required to cure all metastatic bone lesions in 22 patients with CRPC metastatic to bone. </plain></SENT>
<SENT sid="245" pm="."><plain>A new treatment planning framework was introduced to predict the decrease in metastatic burden as a function of the absorbed doses delivered, which could enable personalised treatment of bone metastases with the aim of prolonged survival. </plain></SENT>
</text></p><p><text><SENT sid="246" pm="."><plain>The results showed a strong correlation between metastatic control probability and the degree of variability of the absorbed doses delivered to multiple lesions, with a median PMADMCP=0.95 of 183 Gy. </plain></SENT>
<SENT sid="247" pm="."><plain>A strong correlation between metastatic control probability and minimum lesion absorbed dose was also observed. </plain></SENT>
<SENT sid="248" pm="."><plain>This indicates the limitations of this model alone for treatment planning, since a metastatic burden reduction, rather than complete eradication of metastases can still be considered a good response to treatment. </plain></SENT>
<SENT sid="249" pm="."><plain>Application of the newly proposed method to the clinical data showed that a median PMADMBR=0.95 of 89 Gy would be required to reduce the metastatic tumour burden by 50% in this patient cohort. </plain></SENT>
<SENT sid="250" pm="."><plain>The patient-specific metastatic burden control curves showed that 91% of the patients have a steep gradient of the curve, where a large benefit in terms of metastatic burden reduction could be achieved by a small increase in the patient mean absorbed dose. </plain></SENT>
<SENT sid="251" pm="."><plain>In 50% of patients, the patient mean absorbed doses required to reduce the metastatic burden by half varied by only 21 Gy, whilst differences of 119 Gy were found necessary to eradicate all the lesions. </plain></SENT>
<SENT sid="252" pm="."><plain>The metastatic burden control model could be used to identify patients that would benefit more from treatment. </plain></SENT>
<SENT sid="253" pm="."><plain>For instance, the results for patient 4 suggest that this treatment may not be effective, as it would require very high patient mean absorbed doses to obtain any significant metastatic reduction, which would likely result in myelotoxicity. </plain></SENT>
<SENT sid="254" pm="."><plain>To reduce the risk of toxicity, treatment could also be planned according to the lesions that for a given administered activity receive high absorbed doses and the lesion(s) with low absorbed doses could be treated with a boost dose of external beam radiotherapy. </plain></SENT>
</text></p><p><text><SENT sid="255" pm="."><plain>The predicted absorbed doses for elimination of metastases and metastatic burden reduction were considerably higher than the calculated delivered absorbed doses. </plain></SENT>
<SENT sid="256" pm="."><plain>However, a wide range of lesion absorbed doses in patients treated with 186Re-HEDP are available in the literature. </plain></SENT>
<SENT sid="257" pm="."><plain>Israel et al obtained a mean absorbed dose delivered to lesions of 2.1 Gy GBq−1 from 1.532 GBq (Israel et al 2000) in close agreement with our results. </plain></SENT>
<SENT sid="258" pm="."><plain>Higher absorbed doses were obtained by Maxon et al, with 33 Gy GBq−1 from 1.225 GBq calculated using whole-body planar imaging (Maxon et al 1990); and by Andreou et al with 52 Gy GBq−1 from 1.295 GBq (Andreou et al 2010). </plain></SENT>
<SENT sid="259" pm="."><plain>Differences in lesion absorbed doses are likely due not only to the challenges associated with the heterogeneity of uptake of bone-seeking radiopharmaceuticals and the difficulty to calculate the tumour volume (Bouchet et al 1999, Bouchet and Bolch 1999, Strigari et al 2007), but also to the lack of standardization of imaging and dosimetry protocols. </plain></SENT>
<SENT sid="260" pm="."><plain>Nonetheless, the calculations were based on the relative distribution of absorbed doses delivered to multiple lesions in a given patient. </plain></SENT>
<SENT sid="261" pm="."><plain>Therefore the methodology and conclusions drawn from this study are not affected by the absolute absorbed doses. </plain></SENT>
<SENT sid="262" pm="."><plain>Absolute dosimetry would be required to fully understand the biological effects of the radiation doses delivered and tailoring the treatment to individual patients (Pouget et al 2015). </plain></SENT>
<SENT sid="263" pm="."><plain>Therefore more efforts are required towards improving the reproducibility and repeatability of the absorbed dose as a biomarker of response in molecular radiotherapy. </plain></SENT>
</text></p><p><text><SENT sid="264" pm="."><plain>This study has some limitations. </plain></SENT>
<SENT sid="265" pm="."><plain>The relative biological effectiveness (RBE) and radiosensitivity parameters vary for different radionuclides, tissues and activity distributions. </plain></SENT>
<SENT sid="266" pm="."><plain>The uptake of radiopharmaceuticals used for bone metastases highly depends on the osteoblastic activity for bone-seeking agents and is highly heterogeneous at the microscopic scale, particularly for alpha emitting radionuclides. </plain></SENT>
<SENT sid="267" pm="."><plain>However the limited resolution of clinical imaging systems only allows for macroscopic dosimetry and the assumptions of uniform distribution of activity are often made for bone lesion dosimetry (Liepe et al 2003, Baum et al 2016, Pacilio et al 2016). </plain></SENT>
<SENT sid="268" pm="."><plain>The parameters used in the LQ model have been derived from uniformly distributed absorbed doses delivered by external beam radiotherapy in prostate cancer patients, as these are not available for mCRPC and 186Re-HEDP. </plain></SENT>
<SENT sid="269" pm="."><plain>Different radiobiological parameters would have the effect of shifting the absorbed doses required to produce a given effect to lower or higher values although the relative positions of the curves would remain constant for all patients. </plain></SENT>
<SENT sid="270" pm="."><plain>A change in α from typical prostate cancer cells (0.15 Gy−1) to less radio-resistant cells (0.25 Gy−1) would reduce the patient mean absorbed dose required to kill all the metastases and half the metastatic tumour burden by 31–32%. </plain></SENT>
<SENT sid="271" pm="."><plain>Further clinical studies with pre- and post-therapy imaging would allow the validation and refinement of the parameters used in metastatic burden reduction model. </plain></SENT>
</text></p><p><text><SENT sid="272" pm="."><plain>The use of bone-seeking radiopharmaceuticals is rapidly increasing. </plain></SENT>
<SENT sid="273" pm="."><plain>A survival benefit has been observed in patients treated with 223Ra as compared to placebo and 177Lu-DKFZ-617 PSMA has been shown to induce remission in a patient with metastatic prostate cancer (Kratochwil et al 2015). </plain></SENT>
<SENT sid="274" pm="."><plain>Due to the low number of patients treated and the wide range of absorbed doses reported from fixed and/or weight-based administered activities, absorbed dose response relationships have not yet been established. </plain></SENT>
<SENT sid="275" pm="."><plain>Radiation therapy can be an effective treatment for bone pain relief and 48 Gy in 3 fractions SBRT treatment in patients with multiple oligometastases, have shown promising long-term disease control (Salama et al 2012). </plain></SENT>
<SENT sid="276" pm="."><plain>An on-going clinical trial is investigating the eradication of oligometastases, including bone lesions, in patients with mCRPC (NCT02685397). </plain></SENT>
<SENT sid="277" pm="."><plain>Radiation therapy is typically used in symptomatic and late stages of disease. </plain></SENT>
<SENT sid="278" pm="."><plain>However, implementation of treatment early in the course of the disease may increase quality of life and reduce overall metastatic tumour burden; in turn, delaying disease progression and improving long-term survival. </plain></SENT>
<SENT sid="279" pm="."><plain>This could be of particular relevance for molecular radiotherapy, where radiation is targeted to specific molecular sites and toxicity is limited. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec id="pmbaa5e6fs5"><title><text><SENT sid="280" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="281" pm="."><plain>The metastatic burden reduction model proposed in this study offers the potential to provide individualised treatment and could be used as a patient selection tool by relating potential benefit and toxicity. </plain></SENT>
<SENT sid="282" pm="."><plain>Metastatic burden reduction curves could be predicted from pre-therapy imaging or from therapy imaging, which would enable adaptive treatment planning for repeated administrations. </plain></SENT>
<SENT sid="283" pm="."><plain>This simple tool has the potential to inform patient management by individualising treatment in patients with multiple tumours or metastatic disease undergoing molecular radiotherapy. </plain></SENT>
<SENT sid="284" pm="."><plain>Future studies of treatment response will allow validation and refinement of the model. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="285" pm="."><plain>This work was supported by CRUK and EPSRC support to the Cancer Imaging Centre at ICR and RMH in association with MRC &amp; Department of Health C1060/A10334, C1060/A16464 and a grant from the National Cancer Institute supported by NIH grant number CA86784-02. </plain></SENT>
<SENT sid="286" pm="."><plain>We acknowledge NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden Hospital and The Institute of Cancer Research. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="COMP_INT"><sec id="pmbaa5e6fs6"><title>Conflict of interest</title><p>The authors have no potential conflicts of interest relevant to the subject of this article.</p></sec></SecTag><sec id="pmbaa5e6fs7"><title>Ethical approval</title><p>This article does not contain any studies with animals performed by any of the authors. All patients provided written informed consent to take part in the study, which were approved by the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research Ethics committee.</p></sec><SecTag type="REF"><ref-list content-type="alphabetical"><title>References</title><ref id="pmbaa5e6fbib001"><text><SENT sid="287" pm="."><plain>AndreouMPapanikolosGVamvakasGKotsakisNLyraM201010th IEEE Int. </plain></SENT>
<SENT sid="288" pm="."><plain>Conf. on Information Technology and Applications in Biomedicine (ITAB)3–5 November 201014pp 1–410.1109/itab.2010.5687800 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib002"><text><SENT sid="289" pm="."><plain>BaumR PKulkarniH RSchuchardtCSinghAWirtzMWiessallaSSchotteliusMMuellerDKletteIWesterH J2016177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacyJ. </plain></SENT>
<SENT sid="290" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="291" pm="."><plain>Med.57100610131006–1310.2967/jnumed.115.16844326795286 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib003"><text><SENT sid="292" pm="."><plain>BernhardtPAhlmanHForssell-AronssonE2003Model of metastatic growth valuable for radionuclide therapyMed. </plain></SENT>
<SENT sid="293" pm="."><plain>Phys.30322732323227–3210.1118/1.162885114713089 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib004"><text><SENT sid="294" pm="."><plain>BernhardtPAhlmanHForssell-AronssonE2004Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentrationMed. </plain></SENT>
<SENT sid="295" pm="."><plain>Phys.31262826352628–3510.1118/1.178653115487746 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib005"><text><SENT sid="296" pm="."><plain>BouchetL GBolchW E1999A three-dimensional transport model for determining absorbed fractions of energy for electrons within cortical boneJ. </plain></SENT>
<SENT sid="297" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="298" pm="."><plain>Med.40211521242115–2410616894 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib006"><text><SENT sid="299" pm="."><plain>BouchetL GJokischD WBolchW E1999A three-dimensional transport model for determining absorbed fractions of energy for electrons within trabecular boneJ. </plain></SENT>
<SENT sid="300" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="301" pm="."><plain>Med.40194719661947–6610565793 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib007"><text><SENT sid="302" pm="."><plain>BrennerD JHallE J1999Fractionation and protraction for radiotherapy of prostate carcinomaInt. </plain></SENT>
<SENT sid="303" pm="."><plain>J. </plain></SENT>
<SENT sid="304" pm="."><plain>Radiat. </plain></SENT>
<SENT sid="305" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="306" pm="."><plain>Biol. </plain></SENT>
<SENT sid="307" pm="."><plain>Phys.43109511011095–10110.1016/S0360-3016(98)00438-610192361 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib008"><text><SENT sid="308" pm="."><plain>BrulandO SNilssonSFisherD RLarsenR H2006High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?Clin. </plain></SENT>
<SENT sid="309" pm="."><plain>Cancer Res.126250s6257s6250s–7s10.1158/1078-0432.CCR-06-084117062709 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib009"><text><SENT sid="310" pm="."><plain>ChowEZengLSalvoNDennisKTsaoMLutzS2012Update on the systematic review of palliative radiotherapy trials for bone metastasesClin. </plain></SENT>
<SENT sid="311" pm="."><plain>Oncol.24112124112–2410.1016/j.clon.2011.11.004 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib010"><text><SENT sid="312" pm="."><plain>ColemanR E2001Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat. </plain></SENT>
<SENT sid="313" pm="."><plain>Rev.27165176165–7610.1053/ctrv.2000.021011417967 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib011"><text><SENT sid="314" pm="."><plain>DaleR2004Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapyCancer Biother. </plain></SENT>
<SENT sid="315" pm="."><plain>Radiopharm.19363370363–7010.1089/108497804142507015285884 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib012"><text><SENT sid="316" pm="."><plain>DaleRCarabe-FernandezA2005The radiobiology of conventional radiotherapy and its application to radionuclide therapyCancer Biother. </plain></SENT>
<SENT sid="317" pm="."><plain>Radiopharm.20475147–5110.1089/cbr.2005.20.4715778580 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib013"><text><SENT sid="318" pm="."><plain>DaleR G1985The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapyBr. </plain></SENT>
<SENT sid="319" pm="."><plain>J. </plain></SENT>
<SENT sid="320" pm="."><plain>Radiol.58515528515–2810.1259/0007-1285-58-690-5154063711 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib014"><text><SENT sid="321" pm="."><plain>Denis-BacelarA MChittendenS JDearnaleyD PDivoliAO’SullivanJ MMcCreadyV RJohnsonBDuYFluxG D2017Phase I/II trials of 186Re-HEDP in metastatic castration resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survivalEur. </plain></SENT>
<SENT sid="322" pm="."><plain>J. </plain></SENT>
<SENT sid="323" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="324" pm="."><plain>Med. </plain></SENT>
<SENT sid="325" pm="."><plain>Mol. </plain></SENT>
<SENT sid="326" pm="."><plain>Imaging40620629620–910.1007/s00259-016-3543-x </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib0014a"><text><SENT sid="327" pm="."><plain>DearnaleyD2016Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialLancet Oncol17104710601047–6010.1016/S1470-2045(16)30102-427339115 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib015"><text><SENT sid="328" pm="."><plain>DennisE RJiaXMezheritskiyI SStephensonR DSchoderHFoxJ JHellerGScherH ILarsonS MMorrisM J2012Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancerJ. </plain></SENT>
<SENT sid="329" pm="."><plain>Clin. </plain></SENT>
<SENT sid="330" pm="."><plain>Oncol.30519524519–2410.1200/JCO.2011.36.579122231045 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib016"><text><SENT sid="331" pm="."><plain>ElgqvistJJohanssonB RPartheenKDanielssonA2010Tumor cure probability during alpha-RIT of ovarian cancer with different radiation sensitivityAnticancer Res.30254525512545–5120682981 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib017"><text><SENT sid="332" pm="."><plain>FowlerJChappellRRitterM2001Is alpha/beta for prostate tumors really low?Int. </plain></SENT>
<SENT sid="333" pm="."><plain>J. </plain></SENT>
<SENT sid="334" pm="."><plain>Radiat. </plain></SENT>
<SENT sid="335" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="336" pm="."><plain>Biol. </plain></SENT>
<SENT sid="337" pm="."><plain>Phys.50102110311021–3110.1016/S0360-3016(01)01607-811429230 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib018"><text><SENT sid="338" pm="."><plain>FowlerJ F1989The linear-quadratic formula and progress in fractionated radiotherapyBr. </plain></SENT>
<SENT sid="339" pm="."><plain>J. </plain></SENT>
<SENT sid="340" pm="."><plain>Radiol.62679694679–9410.1259/0007-1285-62-740-6792670032 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib019"><text><SENT sid="341" pm="."><plain>GerweckL EVijayappaSKurimasaAOgawaKChenD J2006Tumor cell radiosensitivity is a major determinant of tumor response to radiationCancer Res.66835283558352–510.1158/0008-5472.CAN-06-053316951142 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib020"><text><SENT sid="342" pm="."><plain>GoyalJAntonarakisE S2012Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastasesCancer Lett.323135146135–4610.1016/j.canlet.2012.04.00122521546 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib021"><text><SENT sid="343" pm="."><plain>GrahamM CScherH ILiuG BYehS DCurleyTDaghighianFGoldsmithS JLarsonS M1999Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancerClin. </plain></SENT>
<SENT sid="344" pm="."><plain>Cancer Res.5130713181307–1810389913 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib022"><text><SENT sid="345" pm="."><plain>IsraelOKeidarZRubinovRIosilevskiGFrenkelAKutenABetmanLKolodnyG MYarnitskyDFrontD2000Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronateJ. </plain></SENT>
<SENT sid="346" pm="."><plain>Clin. </plain></SENT>
<SENT sid="347" pm="."><plain>Oncol.18274727542747–5410.1200/JCO.2000.18.14.274710894875 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib023"><text><SENT sid="348" pm="."><plain>KratochwilCGieselFEderMAfshar-OromiehABenešováMMierWKopkaKHaberkornU2015[177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancerEur. </plain></SENT>
<SENT sid="349" pm="."><plain>J. </plain></SENT>
<SENT sid="350" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="351" pm="."><plain>Med. </plain></SENT>
<SENT sid="352" pm="."><plain>Mol. </plain></SENT>
<SENT sid="353" pm="."><plain>Imaging42987988987–810.1007/s00259-014-2978-125573634 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib024"><text><SENT sid="354" pm="."><plain>LiepeKHliscsRKroppJRungeRKnappF FFrankeW G2003Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastasesJ. </plain></SENT>
<SENT sid="355" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="356" pm="."><plain>Med.44953960953–6012791825 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib025"><text><SENT sid="357" pm="."><plain>LiepeKShintoA2016From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastasesTher. </plain></SENT>
<SENT sid="358" pm="."><plain>Adv. </plain></SENT>
<SENT sid="359" pm="."><plain>Med. </plain></SENT>
<SENT sid="360" pm="."><plain>Oncol.8294304294–30410.1177/175883401664049427482288 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib026"><text><SENT sid="361" pm="."><plain>MaxonH R3rd1990Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancerRadiology176155159155–910.1148/radiology.176.1.16937841693784 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib027"><text><SENT sid="362" pm="."><plain>MillarW T1991Application of the linear-quadratic model with incomplete repair to radionuclide directed therapyBr. </plain></SENT>
<SENT sid="363" pm="."><plain>J. </plain></SENT>
<SENT sid="364" pm="."><plain>Radiol.64242251242–5110.1259/0007-1285-64-759-2422021798 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib028"><text><SENT sid="365" pm="."><plain>MundyG R2002Metastasis: metastasis to bone: causes, consequences and therapeutic opportunitiesNat. </plain></SENT>
<SENT sid="366" pm="."><plain>Rev. </plain></SENT>
<SENT sid="367" pm="."><plain>Cancer2584593584–9310.1038/nrc86712154351 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib029"><text><SENT sid="368" pm="."><plain>O’SullivanJ M2002High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to boneBr. </plain></SENT>
<SENT sid="369" pm="."><plain>J. </plain></SENT>
<SENT sid="370" pm="."><plain>Cancer86171517201715–2010.1038/sj.bjc.660034812087455 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib030"><text><SENT sid="371" pm="."><plain>O’SullivanJ M2006A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to boneEur. </plain></SENT>
<SENT sid="372" pm="."><plain>J. </plain></SENT>
<SENT sid="373" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="374" pm="."><plain>Med. </plain></SENT>
<SENT sid="375" pm="."><plain>Mol. </plain></SENT>
<SENT sid="376" pm="."><plain>Imaging33105510611055–6110.1007/s00259-005-0010-516572306 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib031"><text><SENT sid="377" pm="."><plain>OliveiraS MTeixeiraN JFernandesL2012What do we know about the α/β for prostate cancer?Med. </plain></SENT>
<SENT sid="378" pm="."><plain>Phys.39318932013189–20110.1118/1.471222422755703 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib032"><text><SENT sid="379" pm="."><plain>PacilioM2016Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichlorideEur. </plain></SENT>
<SENT sid="380" pm="."><plain>J. </plain></SENT>
<SENT sid="381" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="382" pm="."><plain>Med. </plain></SENT>
<SENT sid="383" pm="."><plain>Mol. </plain></SENT>
<SENT sid="384" pm="."><plain>Imaging43213321–3310.1007/s00259-015-3150-226266887 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib033"><text><SENT sid="385" pm="."><plain>ParkerC2013Alpha emitter radium-223 and survival in metastatic prostate cancerNew Engl. </plain></SENT>
<SENT sid="386" pm="."><plain>J. </plain></SENT>
<SENT sid="387" pm="."><plain>Med.369213223213–2310.1056/NEJMoa121375523863050 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib034"><text><SENT sid="388" pm="."><plain>PougetJ PLozzaCDeshayesEBoudousqVNavarro-TeulonI2015Introduction to radiobiology of targeted radionuclide therapyFront. </plain></SENT>
<SENT sid="389" pm="."><plain>Med.21210.3389/fmed.2015.00012 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib035"><text><SENT sid="390" pm="."><plain>SalamaJ K2012Stereotactic body radiotherapy for multisite extracranial oligometastasesCancer118296229702962–7010.1002/cncr.2661122020702 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib036"><text><SENT sid="391" pm="."><plain>SalujaRCheungPZukotynskiKEmmeneggerU2016Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: from chemohormonal therapy to stereotactic ablative radiotherapy of oligometastasesUrol. </plain></SENT>
<SENT sid="392" pm="."><plain>Oncol.34225232225–3210.1016/j.urolonc.2016.02.01627008982 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib037"><text><SENT sid="393" pm="."><plain>SolowayM SHardemanS WHickeyDRaymondJToddBSolowaySMoinuddinM1988Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scanCancer61195202195–20210.1002/1097-0142(19880101)61:1&lt;195::AID-CNCR2820610133&gt;3.0.CO;2-Y3334948 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib038"><text><SENT sid="394" pm="."><plain>StrigariLSciutoRD’AndreaMPasqualoniRBenassiMMainiC L2007Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulationEur. </plain></SENT>
<SENT sid="395" pm="."><plain>J. </plain></SENT>
<SENT sid="396" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="397" pm="."><plain>Med. </plain></SENT>
<SENT sid="398" pm="."><plain>Mol. </plain></SENT>
<SENT sid="399" pm="."><plain>Imaging34103110381031–810.1007/s00259-006-0302-417237963 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib039"><text><SENT sid="400" pm="."><plain>TreeA CKhooV SEelesR AAhmedMDearnaleyD PHawkinsM AHuddartR ANuttingC MOstlerP Jvan AsN J2013Stereotactic body radiotherapy for oligometastasesLancet Oncol.14e28e37e28–3710.1016/S1470-2045(12)70510-723276369 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib040"><text><SENT sid="401" pm="."><plain>TuS-M2001Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trialLancet357336341336–4110.1016/S0140-6736(00)03639-411210994 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib041"><text><SENT sid="402" pm="."><plain>WalrandSHaninF-XPauwelsSJamarF2012Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: assuming similar pharmacokinetics, 125 Sn–177 Lu is superior to 90 Y–177 Lu in peptide receptor radiotherapyPhys. </plain></SENT>
<SENT sid="403" pm="."><plain>Med. </plain></SENT>
<SENT sid="404" pm="."><plain>Biol.57426310.1088/0031-9155/57/13/426322705627 </plain></SENT>
</text></ref><ref id="pmbaa5e6fbib042"><text><SENT sid="405" pm="."><plain>WangJ ZGuerreroMLiX A2003How low is the alpha/beta ratio for prostate cancer?Int. </plain></SENT>
<SENT sid="406" pm="."><plain>J. </plain></SENT>
<SENT sid="407" pm="."><plain>Radiat. </plain></SENT>
<SENT sid="408" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="409" pm="."><plain>Biol. </plain></SENT>
<SENT sid="410" pm="."><plain>Phys.55194203194–20310.1016/S0360-3016(02)03828-212504054 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
